Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7414089 | 0.99 | HTR4 (0.58) | HTR4DRD2 | |
| SCHEMBL7421953 | 0.86 | DRD2 (0.49) | HTR4DRD2 | |
| SCHEMBL505450 | 0.85 | HTR4 (0.58) | HTR4DRD2 | |
| SCHEMBL7423609 | 0.83 | HTR4 (0.66) | HTR4 | |
| SCHEMBL505612 | 0.81 | HTR4 (0.64) | HTR4 | |
| Hydrochloric Acid SCHEMBL7357759 | 0.80 | HTR4 (0.63) | HTR4 | |
| SCHEMBL4143183 | 0.79 | HTR4 (0.70) | HTR4 | |
| SCHEMBL7331083 | 0.76 | NR4A2 (0.54) | HTR4 | |
| SCHEMBL8132871 | 0.75 | HTR4 (0.52) | HTR4 | |
| SCHEMBL13600871 | 0.75 | DRD2 (0.51) | HTR4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205410-B2 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| EP-1140915-B1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2005-06-15 | — | — | EP | disclosed |
| US-20030181456-A1 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2003-09-25 | — | — | US | disclosed |
| US-6544997-B1 | E.g., hypermotility, irritable bowel syndrome, bowel hypersensitivity and the reduction of pain associated with gastrointestinal hypersensitivity and/or hyperactivity | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-04-08 | — | — | US | disclosed |
| EP-1140915-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037461-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181456-A1 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | HRH2, ALK, CBR1 | HTR4 144/4885DRD2 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.